English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45073/58249 (77%)
造訪人次 : 2379936      線上人數 : 166
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6521


    題名: 高血壓病人進行血管收縮素接受器阻斷劑相同療效藥品替代之評估
    ARB therapeutic interchange evaluation in patients with hypertension
    作者: 黃子芸
    Tzu-yun Huang
    貢獻者: 藥學研究所
    關鍵詞: 相同療效藥品替代
    治療相等性藥品
    血管收縮素接受器阻斷劑
    高血壓
    therapeutic interchange
    therapeutic equivalents
    angiotensin Ⅱ receptor blockers
    hypertension
    日期: 2005
    上傳時間: 2009-09-11 16:58:17 (UTC+8)
    摘要: 研究目的:評估高血壓病人從其他血管收縮素接受器阻斷劑(ARBs)換成candesartan之後對治療結果的影響,評估藥品替代之後的療效、安全性和病人滿意度。療效評估包括換藥前後的血壓變化和達目標血壓值的人數比率,安全性則是評估病人將藥物換成candesartan是否產生副作用或嚴重不良反應。
    研究方法:這是非隨機分派(non-randomized)、開放性(open labeled)且自我比較(self-controlled)的研究。依據收案條件納入2004年8月至2004年11月所有使用candesartan的門診病人,開始進入研究過程。研究進行的時間從2004年8月至2005年5月止,為期九個月。在藥物替換成candesartan之後,分別在第2至4週、12週、24週,評估病人回醫院門診測量的血壓,及換藥之前病歷的血壓紀錄,換藥後2至4週、12週和24週的血壓分別和換藥之前的血壓比較,評估其療效。除了評估血壓值,也評估病人達到目標血壓值的人數比率,比較換藥前和換藥後符合目標血壓值的人數比率。副作用是以電話訪談的方式進行追蹤,詢問是否產生副作用或發生嚴重不良反應,在第2至4週、12週和24週分別進行第一次、第二次和第三次評估,並調查病人對於換藥結果的滿意度。收集紀錄病人的血壓值和副作用資料並加以整理,之後進行統計分析。
    研究結果:依據納入和排除標準共納入了586位病人,而最後有494位病人納入本研究,進行第一次的電話訪談。訪談的494人中其平均年齡為61.7±12.4歲,有53%是男性,47%是女性。換藥前、換藥後2至4週、12週和24週,病人的血壓值分別為143.3/86.1, 140.8/84.1, 137.9/82.9和137.0/82.6 mmHg,和換藥前比較具有明顯的差異(p<0.01)。病人達到目標血壓值的人數及其比率,換藥前是142人(37%),換藥後2至4週是142人(37%),換藥後12週是160人(41%),和換藥前比較並沒有明顯差異,而換藥後24週是182人(47%),和換藥前比較具有顯著差異(p<0.01)。產生副作用的比率在藥品替代之後2至4週、12週和24週分別為103人(21%),26人(6%)和4人(1%),換藥後12週及24週的副作用發生率和換藥後2至4週比較,有明顯降低(p<0.001),而換藥後24週的副作用發生率和12週比較,也有明顯降低(p=0.001),故三次病人產生的副作用發生率明顯減少。然而,有68人(15%)由於副作用或血壓控制不滿意停用candesartan,換成其他降血壓藥治療。藥品替代之後2至4週、12週和24週的滿意度分別為494位病人中有428人(87%)滿意、425位病人中有400人(94%)滿意和389位病人中有378人(97%)滿意,三組之間的滿意度並沒有顯著差異。
    結論:本研究納入494位病人,其中有389人(79%)完成三次評估,約八成的病人持續使用candesartan至少六個月以上,而且有更好的降血壓效果,大多數的副作用是在病人換藥後2至4週產生,隨著藥品使用時間的延長而自行緩解,並沒有產生任何嚴重的不良反應,符合臨床上藥品有效性和安全性的要求,而且近九成的病人滿意candesartan的治療結果,顯示candesartan適合作為其他血管收縮素接受器阻斷劑治療高血壓的替代藥品。
    Objective: To evaluate clinical outcomes of subjects whose therapy was converted from other ARBs to candesartan, determine the efficacy and safety of candesartan in patients with hypertension, and patients’ satisfaction. Efficacy analysis was the changes in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange. Safety analysis was to evaluate if patients have side effects or severe adverse drug reaction.
    Methods: A non-randomized, open-labeled and self-controlled study. All eligible outpatients taking candesartan entered into the study from August 2004 to November 2004. After converting to candesartan, baseline and blood pressure during 2 to 4-week, 12-week and 24-week clinic visits were compared to assess efficacy. The rate of subjects attaining blood pressure goal after conversion were compared to baseline. Side effects were followed up by telephone interview at 2 to 4, 12 and 24 weeks. Patients’ satisfaction with outcome of therapeutic interchange was assessed. The values of blood pressure and side effects were recorded and collected.
    Results: Eligible outpatients were 586 patients, and 494 patients were enrolled in the study and completed the first evaluation by telephone interview. The 494 interviewed patients had a mean age of 61.7 ± 12.4 years, 53% were male and 47% were female. Mean baseline blood pressure, 2 to 4 - week, 12 - week, and 24 - week after drug conversion were 143.3/86.1, 140.8/84.1, 137.9/82.9, and 137.0/82.6 mmHg, respectively(p<0.01 vs. baseline). The rate of subjects achieving blood pressure goal were 142(37%)at baseline, 142(37%)at 2 to 4 weeks, and 160(41%)at 12 weeks(p values no significant difference vs. baseline)and 182(47%)at 24 weeks(p< 0.01 vs. baseline), respectively. The incidence of side effects at 2 to 4 weeks, 12 weeks and 24 weeks were 21%(n=103), 6%(n=26), and 1%(n=4), respectively(p<0.001 vs. 2 to 4 weeks, p=0.001 vs. 12 weeks). Sixty-eight(15% of all subjects)discontinued candesartan due to side effects or unsatisfying blood pressure. Patients’ satisfaction at 2 to 4, 12, and 24 weeks were 428(87%) of the 494 patients, 400(94%)of the 425 patients and 378(97%)of the 389 patients, respectively(P>0.05 vs. 2 to 4 weeks).
    Conclusions: There were 494 patients enrolled in the study and 389 (79%)patients completed the study. Patients who can tolerate the conversion from ARBs to candesartan at least six months achieved better blood pressure control. Most side effects appeared during 2 to 4 weeks and resolved steadily with time, and no serious adverse drug reactions happened. Approximately 90 percentages of patients were satisfied with clinical outcomes of therapeutic interchange. Candesartan is an appropriate substitution for other angiotensin Ⅱ receptor blockers.
    資料類型: thesis
    顯示於類別:[藥學系] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    摘要.doc31KbMicrosoft Word89檢視/開啟
    摘要.pdf73KbAdobe PDF159檢視/開啟
    摘要.ppt151KbMicrosoft Powerpoint148檢視/開啟
    摘要.ps559KbPostscript51檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋